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leep disturbances are nearly universal in psy-
chiatric disorders,especially mood disorders.Research
investigating associations between sleep and affective ill-
ness has largely focused on depression and major depres-
sive disorder (MDD).This paper will review cross-sec-
tional associations between sleep disturbance and MDD,
longitudinal risk relationships between insomnia and the
subsequent development of depression,the implications
of insomnia for clinical course,treatment response,and
relapse in MDD,and lastly the effectiveness of targeted
sleep interventions in improving sleep and depression
outcomes.Although not the primary focus, findings in
bipolar disorder will be briefly covered.
Sleep complaints and depression 
are bidirectionally related
As many as 90% of patients with depression will have
sleep quality complaints.
1 About two thirds of patients
undergoing a major depressive episode will experience
insomnia, with about 40% of patients complaining of
problems initiating sleep (sleep onset difficulties),main-
taining sleep (frequent awakenings),and/or early-morn-
ing awakenings (delayed or terminal insomnia), and
many patients reporting all three.
2,3 Hypersomnia occurs
in about 15% of patients. Sleep problems sometimes
emerge as a symptom of depression or as a side effect of
treatment.Insomnia occurring within major depressive
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The majority of individuals with depression experience
sleep disturbances. Depression is also over-represented
among populations with a variety of sleep disorders.
Although sleep disturbances are typical features of depres-
sion, such symptoms sometimes appear prior to an episode
of depression. The bidirectional associations between sleep
disturbance (especially insomnia) and depression increase
the difficulty of differentiating cause-and-effect relation-
ships between them. Longitudinal studies have consistently
identified insomnia as a risk factor for the development of
a new-onset or recurrent depression, and this association
has been identified in young, middle-aged, and older
adults. Studies have also observed that the combination of
insomnia and depression influences the trajectory of
depression, increasing episode severity and duration as
well as relapse rates. Fortunately, recent studies have
demonstrated that both pharmacological and nonpharma-
cological interventions for insomnia may favorably reduce
and possibly prevent depression. Together, these findings
suggest that sleep-related symptoms that are present
before, during, and/or after a depressive episode are
potentially modifiable factors that may play an important
role in achieving and maintaining depression remission.     
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secondary symptom of depression.Depression is identi-
fied as the most frequent cause of chronic insomnia in
both clinical and epidemiological samples.
4,5 However,
sleep problems often appear prior to the onset of a new
or recurrent episode of major depression.Patients with
mood disorders commonly report that insomnia
appeared either before (40%) or at the same time (22%)
as other depression symptoms.
6 Evidence that insomnia
can be a prodromal symptom in MDD
7 suggests that
sleep may be involved in the pathogenesis of depression.
Chronic insomnia can also exist months or years before
an episode of depression,and shares consistent clinical
features,course,and response to treatment as insomnia
during MDD.Thus,a recent National Institutes of Health
conference suggested that “comorbid”insomnia may be
a more appropriate term than “secondary.”
8
Depression is also overrepresented in individuals with
sleep disorders.
9As many as 24% to 58% of individuals
with sleep disordered breathing (eg, obstructive sleep
apnea) meet the criteria for depression.
10-12 One general
population survey of 18 980 adults reported that 0.8% of
the sample had both sleep disordered breathing and
MDD.
13 As many as 18% of individuals diagnosed with
MDD also had sleep disordered breathing,and 17.6% of
individuals with sleep disordered breathing were diag-
nosed with MDD. Patients with narcolepsy, a disorder
characterized by excessive daytime sleepiness,similarly
have elevated rates of depression;as many as 28% to 57%
have elevated depression symptoms,
14,15 and in one sample,
20% met current or past criteria for depression.
16As many
as three quarters of individuals with delayed sleep phase
syndrome,a circadian rhythm disorder that leads to sec-
ondary insomnia and negatively impacts daytime function-
ing,have a past or current history of depression,
17 and such
individuals report poorer sleep quality and more depres-
sion.
18 Restless legs syndrome also has an increased asso-
ciation with depression
19;as many as 53% of clinic patients
with restless legs syndrome or periodic limb movements
have elevated depression ratings.
14,20
Insomnia is a risk factor 
for developing depression
A number of longitudinal studies support the notion that
insomnia is a risk factor for developing both first-onset
and recurrent MDD.In the National Institute of Mental
Health Epidemiologic Catchment Area study sample
(n=7954),individuals with persistent insomnia (present
at both baseline and 1-year follow-up) were much more
likely to develop a new depressive episode at follow-up
compared with individuals whose insomnia resolved by
follow-up (odds ratio (OR)=39.8,95% confidence inter-
val (CI)=19.8–80.0 vs OR=1.6, 95% CI=0.5–5.3).
21
Subsequent analyses
22 revealed that of all the symptoms
of depression,sleep problems were the most prevalent
(13.6%),and those with sleep problems had the highest
relative odds (7.6 times) of developing a new-onset major
depressive episode during the next year compared with
those without sleep problems.Sleep problems also iden-
tified 47% of individuals who develop depression in the
following year, more than any other depression symp-
tom.Thus,sleep problems had the strongest predictive
value of who would develop MDD.In a different subse-
quent analysis,
23 individuals with insomnia but without
any psychiatric disorders were also more likely to
develop a new-onset MDD in the subsequent year
(OR=5.4,95% CI=2.6–11.3) compared with individuals
with neither insomnia or psychiatric disorders. The
authors suggested that the early diagnosis and treatment
of insomnia may prevent subsequent depression.
In a longitudinal study of 979 young adults,
24 insomnia
increased the relative risk for depression fourfold (95%
CI=2.2–7.0) over a 3-year period,even after controlling for
baseline depression symptoms. In another longitudinal
study in 591 young adults,depression and insomnia symp-
toms were assessed six times over 21 years.
25The presence
of insomnia either with or without comorbid depression
tended to be highly stable over time.Between 17% and
50% of cases without depression but with 2 weeks or more
of insomnia in the past 6 months developed a major
depressive episode at a subsequent time point.The pres-
ence of insomnia (without depression) and depression
(without insomnia) were not longitudinally related to each
other.Insomnia comorbid with depression,however,was
longitudinally related to having both.
Two other studies have similarly identified insomnia as a
risk factor for depression over long follow-up periods.
One study
26 followed over 1000 male medical students for
a median of 34 years (range 1–45). Both insomnia and
difficulty sleeping under stress in medical school
increased the risk for subsequent depression (relative
risk and 95% CI, respectively, 1.9, 1.2–3.2 and 1.7,
1.1–2.5).Another study followed 1244 middle-aged adults
for 12 years.
27 Chronic insomnia was reported in a third
of women and a quarter of men;three quarters of those
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year follow-up.Only women who reported insomnia at
baseline were significantly more likely to report feeling
depressed at follow-up (OR=4.1, 95% CI=2.1–7.2),
whereas the relationship in men was not significant
(OR=1.3,95% CI=0.8–2.3).
Similar risk relationships have been identified in older
adults.In a study
28 involving 147 older adults without a
prior history of mental illness,the presence of insomnia
(scoring 1 or higher on any of the Hamilton Rating Scale
for Depression sleep items) was assessed at two time
points separated by 1 year. Participants with insomnia
that persisted at both time points were more likely to
develop a first episode of depression during the 1-year
follow-up period (OR=6.9,95% CI=1.3–36.1) compared
with participants who scored 0 on the three sleep items
at both time points.In a larger longitudinal study of 524
older adults,
29 sleep disturbances at baseline predicted
depression 2 to 3 years later (odds ratio=3.2, 95%
CI=1.5–6.8), after adjusting for other risk factors.
Individuals with persistent sleep disturbances were more
likely to be depressed than individuals whose insomnia
had resolved at follow-up or individuals who developed
insomnia during follow-up.
Insomnia does not precede depression in all cases,and
nor do the above findings prove causal relationships
between insomnia and depression.Further,ample evi-
dence suggests that both depression and its treatment can
induce sleep disturbances.Thus,although there are bidi-
rectional influences between insomnia and depression,
the consistency of these longitudinal observations
strongly suggests that insomnia poses significant risk for
depression. Insomnia may simply be a proxy for other
causal factors,or insomnia may mediate the development
and severity of depression.If the latter is the case,this
may have important implications for preventing the
onset or recurrence of depression.Further research will
be necessary to determine whether such prophylactic
treatments can reduce the incidence of depression in
individuals with sleep problems.
Insomnia is a risk factor for 
poor depression outcomes
Acute depression remission
Insomnia impacts the trajectory of MDD,increasing the
severity and duration of an episode of depression.Poor
subjective sleep quality before starting treatment may
predict reduced treatment response.For example,pre-
treatment sleep quality ratings were higher in women
who had significant improvements in mood while under-
going interpersonal therapy compared with women
whose depression did not remit.
30 Similarly,poor sleep
quality was associated with a poorer response to com-
bined pharmacological and psychological treatments of
depression.
31 Studies have also associated sleep distur-
bances with suicide.Suicidal individuals have higher rates
of poor sleep quality,
32 insomnia,and hypersomnia.
33,34 In
one study,insomnia severity was one of several clinical
features that prospectively predicted suicide within 1
year.
35Analogous findings associating sleep with depres-
sion severity and suicide have been reported adolescence.
In a sample of 553 adolescents with MDD,
36 73% had
sleep disturbance:54% had insomnia,9% had hypersom-
nia,and 10% had both.Adolescents with both insomnia
and hypersomnia were the most severely depressed,and
those with either insomnia or hypersomnia were more
depressed compared with those without sleep distur-
bance.Sleep disturbance was also associated with having
more depressive symptoms and comorbid anxiety disor-
ders.Sleep disturbances are also associated with elevated
risk for suicide in children and adolescence.
37 In a sample
of 135 children and adolescents with MDD,
38 patients
who reported current or past suicidal ideation with a plan
were significantly more likely to have insomnia (72%)
compared with nonsuicidal youth (46%).
Pigeon and colleagues
39 examined the impact of persistent
insomnia on response to treatment in older adults with
MDD.Mean scores across the baseline and 3-month time
points on the three sleep items of the Hopkins Symptom
Check List-20 (HCSL) were used to categorize patients
into persistent insomnia (n=207),intermediate insomnia
(n=1301),and no insomnia (n=293) groups.There was a
dose-response relationship between the level of insomnia
and presence MDD at 6 months,with 44% of “persistent
insomnia,”29% of “intermediate insomnia,”and 14% of
“no insomnia”groups meeting DSM-IV criteria for MDD.
Those with persistent insomnia were more likely to remain
depressed and/or achieve less than 50% clinical improve-
ment (HCSL) at 6 and 12 months. In another study,
40
insomnia persisted in patients who remained depressed
during 4 weeks of antidepressant treatment (imipramine
or amitriptyline).These results suggest that insomnia,par-
ticularly when persistent, may perpetuate depression
and/or impair treatment response.
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Patients who are treated successfully for MDD report
improved sleep quality.
41 Improvements in subjective
sleep quality also appear to be related to lower recur-
rence rates of depression.
42The recovery of poor subjec-
tive sleep quality in older adults with remitted depression
predicted which patients remained well during 1 year of
follow-up with maintenance interpersonal psychother-
apy after switching to pill placebo
43;90% of the patients
with improved sleep quality remained well, compared
with 33% of patients with persistent insomnia who
remained well.
Unfortunately,sleep problems frequently do not sponta-
neously resolve with typical treatments for depression.
In fact,insomnia is the most common residual symptom
following remission from depression,occurring in 44%
to 51% of treatment responders following cognitive-
behavioral therapy or pharmacotherapy for depres-
sion.
44,45 Patients with residual symptoms are 3 to 6 times
more likely to relapse than patients in full remission,
46
and relapse may occur more quickly in the presence of
residual symptoms.
47 Left untreated,insomnia increases
the risk for relapse of MDD. In one small study of
patients with recurrent MDD who were currently in
remission for at least 4 weeks,
7 progressively greater lev-
els of subjective sleep disturbance preceded the recur-
rence of a depressive episode.Thus,residual symptoms
generally,and those related to insomnia specifically,con-
fer significant risk for relapse of MDD.
Given the high degree of residual insomnia following
antidepressant treatments,targeted insomnia interven-
tions may be more effective in improving insomnia,and
therefore resulting in better depression outcomes.
Insomnia-specific interventions may therefore lead to
remission that is more stable,extending the time between
depressive episodes and possibly lowering relapse rates.
Treating sleep favorably impacts 
the trajectory of depression
Insomnia
Insomnia and other sleep disturbances often go unrecog-
nized;however,treating insomnia may lessen depression
severity and hasten recovery. The strongest evidence
comes from a recent placebo-controlled, double-blind
study in which 545 patients meeting criteria for both
MDD and insomnia received fluoxetine (a selective sero-
tonin reuptake inhibitor,SSRI) in the morning and were
randomly assigned to placebo or eszopiclone (a benzodi-
azepine receptor agonist) in the evening.Across the 8-
week treatment trial,self-reported measures of sleep and
depression showed significantly greater progressive
improvement in those assigned to coadministration of flu-
oxetine and eszopiclone.Notably,by the end of the trial,
there were significantly more responders (59% vs 48%)
and remitters (42% vs 33%) in the fluoxetine/ eszopiclone
group,suggesting that improving sleep may enhance the
antidepressant response.After the 8-week treatment trial,
patients received 2 weeks of continued SSRI and placebo.
Hypnotic discontinuation over this 2-week period was not
associated with a rebound in either insomnia or depres-
sion.
48 A smaller double-blind trial of 50 patients with
MDD treated with fluoxetine and either hypnotic (the
benzodiazepine clonazepam) or placebo,however,failed
to find sustained improvements in depression over a 3-
month period in the hypnotically-treated group.
49 In
another placebo-controlled trial,
50 190 depressed adult
patients who had persistent insomnia in the presence of
at least 2 weeks of effective treatment with SSRIs were
assigned to placebo or the hypnotic zolpidem (a benzodi-
azepine receptor agonist). Compared with the placebo
group, patients assigned to the hypnotic had improved
self-reported sleep, daytime function, and well-being.
Thus,pharmacotherapy for insomnia did not impair the
antidepressant response in patients who had already
responded to pharmacotherapy for depression.Studies in
which benzodiazepines such as clonazepam,lorazepam,
and lormetazepam were used as an adjunctive treatment
also showed that depressed patients had improved sleep
without worsening of depression.
49,51,52 Rather, each of
these studies suggested that adjunctive benzodiazepines
may be associated with improved response,more rapid
response,greater compliance,or a greater percentage of
responders.
There are fewer studies investigating nonpharmacologi-
cal interventions for insomnia in depression.Behavioral
interventions include stimulus control instructions
53 and
sleep restriction.
54 Cognitive-behavioral therapy for
insomnia (CBT-I) usually includes an additional cogni-
tive component such as correcting dysfunctional beliefs
about sleep (eg,“I must get 8 hours of sleep to be able to
function the following day.”).These nonpharmacological
interventions have been consistently demonstrated to be
effective in improving sleep in primary insomnia,
55-57 as
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psychiatric conditions (see ref 58 for review).The effects
of CBT-I have been demonstrated to last up to 2 years in
primary insomnia.
59 This has particular relevance for
treating insomnia in MDD,as individuals who remain in
insomnia remission are more likely to remain in depres-
sion remission.
7,28
One randomized control trial of CBT-I in patients with
MDD has been reported.
60 Individuals with comorbid
insomnia and MDD (n=30) received 12 weeks of open-
label SSRI (up to 20 mg of escitalopram),while concur-
rently receiving 5 weekly and 2 biweekly sessions of
either CBT-I or a control therapy (quasi-desensitization).
Compared with the control group, those assigned to
SSRI and CBT-I coadministration had higher rates of
both depression remission (62% to 33%) and insomnia
remission (50% to 8%).Although the difference in rates
of depression remission did not reach statistical signifi-
cance, likely a function of the small sample size, these
findings suggest that insomnia and possibly depression
can be successfully improved using nonpharmacological
interventions.
Several studies have reported improvements in depres-
sion severity following CBT-I. One small pilot study
61
evaluated CBT-I for comorbid mild depression and
insomnia,finding that all 8 participants who completed
the CBT-I intervention no longer met criteria for insom-
nia, and all but one participant reported normal post-
treatment depression scores (Beck Depression Inventory
scores <9).Two other reports that examined individuals
with and without depression documented equivalent
improvements in sleep following CBT-I
62 or a self-help
intervention that consisted of stimulus control, relax-
ation,and cognitive components
63;improvements in sleep
were also associated with significant reductions in self-
reported depression severity.
Further controlled trials are needed to replicate these
findings,to examine whether the resolution of insomnia
following CBT-I and/or pharmacotherapy leads to longer
periods of depression remission,and whether targeted
insomnia interventions favorably impact sleep and
depression in individuals whose insomnia emerges dur-
ing treatment or remains a residual symptom following
an adequate antidepressant trial.These initial findings,
however, suggest that both hypnotics and CBT-I may
lead to improvements in depression and insomnia symp-
toms, and therefore such interventions may lead to
depression remission that is more stable.
Hypersomnia and fatigue
Less research has examined the impact of hypersomnia on
depression and its treatment.Although the symptom of
hypersomnia is reported less often in patients with MDD,
daytime sleepiness and fatigue are common symptoms of
depression,and are also prevalent in the prodromal and
residual phases of MDD.Such symptoms can occur inde-
pendently,or they may occur secondarily to sleep continu-
ity difficulties or insomnia comorbidity,as well as short- or
long-term side effects of antidepressant medications.
Fatigue is the second most common residual symptom in
depression.
45 Like insomnia,treating daytime sleepiness
and fatigue within the context of depression may favorably
impact remission.
Modafinil is a novel psychostimulant approved to treat
excessive daytime sleepiness in narcolepsy,sleep apnea,and
shift work sleep disorder.Modafinil has several properties
that make it a potential candidate to treat residual sleepi-
ness and fatigue in MDD;it is relatively well-tolerated,and
unlike classic stimulants,modafinil has less euphoric effects
and is thought to have lower abuse potential. Several
uncontrolled,open-label trials in depression have reported
improvements in sleepiness and fatigue following modafinil
(see ref 64 for review).Two placebo-controlled trials
65,66 of
modafinil in partial responders to SSRI therapy for MDD
failed to find persistent improvements in fatigue,sleepiness,
or depressive symptom severity.In a retrospective analy-
sis,
67 the data were pooled across these two studies.Only
individuals with sleepiness,fatigue,and depression scores
in the moderate and higher range were included (n=348,
77% of the original samples).Compared with the placebo
group, the modafinil group had statistically significant
improvements in overall clinical condition, depressive
symptoms,and fatigue at week 1 and at the end of treat-
ment 6 to 8 weeks later,but not during any of the interme-
diary time points.Although efficacy and longitudinal data
are currently lacking,modafinil may provide some benefits
in reducing fatigue and sleepiness in depression.
Sleep disturbance and bipolar depression
Although less studied,sleep disturbances are character-
istic features in bipolar depression (BD) with decreased
need for sleep symptomatic in episodes of mania, and
either insomnia or hypersomnia symptomatic in episodes
of depression. Sleep also appears to be significantly
impaired during euthymic periods,with elevated levels
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rhythm stability.
68 Such sleep disturbances may also be
related to the pathogenesis of depression and especially
mania,with increases in sleep problems just prior to an
episode that continue to worsen within an episode.
According to a systematic review of prodomal symptoms
among patients with BD,
69 sleep disturbance was the
most common prodome for mania (reported by a median
of 77% of individuals),and the sixth most common pro-
drome for depression (reported by a median of 24%).
Targeting sleep during mania may shorten episode dura-
tion.Although these findings suggest that treating sleep
disturbance may prolong remission and prevent relapse,
no prospective data yet exist supporting this notion.
However,treatments that target sleep/wake regularity
may help reduce relapse in BD.Stabilizing social rhythms
with interpersonal and social rhythm therapy is effective
in reducing relapse in bipolar disorder.
70 For further
information on sleep and circadian rhythm disturbances
in BD,see the following recent reviews.
68,71,72
Treatment implications
In depressed patients with sleep complaints,referral to a
sleep disorders specialist may help determine whether
there is an underlying comorbid sleep disorder such as
sleep apnea or restless legs syndrome that may cause or
contribute to the symptoms of depression. Although
insomnia is the sleep disorder with the strongest associ-
ation with depression,other prevalent sleep disorders (ie,
sleep apnea and restless legs syndrome) can lead to
symptoms of insomnia,and they are overly represented
in patients with depression and vice versa.
Based on the findings reviewed above,it is important for
clinicians to carefully evaluate sleep symptoms in
patients with depression.The emerging view that insom-
nia is commonly comorbid with depression,rather than
simply secondary to depression, suggests that both
insomnia and depression may warrant specific treatment
in many cases.Although there have been few random-
ized,controlled treatment trials on insomnia comorbid
with depression,the available evidence suggests the effi-
cacy of several treatment approaches.
Antidepressant pharmacotherapy alone
In most patients treated successfully with antidepres-
sants, sleep symptoms improve in parallel with other
depressive symptoms.This is true even with relatively
“alerting”drugs such as SSRIs.However,a substantial
minority of patients experience increased sleep distur-
bance with SSRIs and bupropion,either in the form of
insomnia or restless legs symptoms.Direct comparisons
confirm that more “sedating”antidepressant drugs such
as nefazodone and amitriptyline improve sleep symp-
toms and polysomnographic findings to a greater degree
than SSRIs.
7,73,74 Nefazodone also showed greater sleep
improvement than depression-specific psychotherapy in
one study.
75Thus,among patients who present with sig-
nificant insomnia at the time of depression,selection of
a more sedating antidepressant drug,such as mirtazap-
ine,may be reasonable.If the risks of a tricyclic antide-
pressant or full-dose trazodone are reasonable in a spe-
cific patient,these might also be considered.
Antidepressant plus hypnotic
For most patients, the favorable risk-benefit profile of
SSRI and SNRI drugs warrant their use as first-line
agents.Among patients with comorbid insomnia,benzo-
diazepine receptor agonist hypnotics can be an effica-
cious adjunctive treatment.For instance,the combination
of eszopiclone plus fluoxetine has been shown to be asso-
ciated with greater sleep improvement,and strong trends
toward an increased rate of depression response,com-
pared with treatment with fluoxetine alone.
48,76 Older
studies also suggest that depression outcomes are not
adversely impacted by the addition of a benzodiazepine
to other antidepressant treatment,and that this strategy
may improve compliance.
49,51
Antidepressant plus low-dose trazodone or doxepin
Although no large randomized clinical trials have been
conducted, smaller studies suggest that the addition of
low-dose (50 to 100 mg) trazodone to an SSRI or
monoamine oxidase inhibitor can improve insomnia
comorbid with depression.
77 In one placebo-controlled
study
77 of adjunctive trazodone, a good hypnotic
response was observed in 67% with trazodone and only
13% with placebo. Excessive sedation is sometimes
observed because of the relatively long duration of
action of trazodone. In a case series of patients with
insomnia associated with fluoxetine,
78 adjunctive tra-
zodone was stopped for excessive sedation in 5 of 21
patients (24%).There is also a potential for “serotonin
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79 in patients treated with both an SSRI and
low-dose trazodone,although such cases are apparently
rare.
One potential advantage of prescribing adjunctive med-
ications (either a sedating antidepressant or a benzodi-
azepine receptor agonist),in contrast to a sedating anti-
depressant alone,is that the adjunctive medication can
be adjusted or discontinued if a patient’s sleep distur-
bance improves while the other antidepressant agent is
maintained.
Depression treatment plus behavioral treatment for
insomnia
A number of studies have suggested that sleep-focused
psychotherapies and behavioral therapies are efficacious
in patients with comorbid insomnia and depression,
80
although some of these studies have suggested that the
response rate for cognitive-behavioral treatment of
insomnia may be lower in insomnia patients with comor-
bid depression.However,recent results from a small con-
trolled clinical trial of depression pharmacotherapy com-
bined with cognitive-behavioral therapy for insomnia
showed improved sleep and depression outcomes com-
pared with pharmacotherapy combined with an inactive
therapy control.
60
Conclusions
Symptoms of insomnia and depression share bidirec-
tional relationships.Cross-sectional studies show a strong
relationship between symptoms of depression and insom-
nia, and insomnia is longitudinally associated with the
development of depression and poor treatment out-
comes.Evidence that sleep strongly influences both the
development and trajectory of depression, impacting
episode frequency,severity and duration,suggests that
sleep-related symptoms may be important and modifi-
able risk factors to prevent depression and/or achieve
and maintain depression remission.Patients with mood
disorders who have sleep disturbances should be care-
fully evaluated.Other sleep disorders,comorbidity with
another medical or psychiatric disorder,and medication
side effects should be considered in patients with insom-
nia or hypersomnia symptoms.Recent evidence suggests
that interventions for insomnia, which include both
behavioral and psychological treatments and pharma-
cotherapy,may be helpful in depression,but further con-
trolled trials are needed. ❏
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Alteraciones del sueño y depresión: 
relaciones riesgosas para depresiones 
posteriores y repercusiones terapéuticas
La mayoría de los sujetos con depresión presentan
alteraciones del sueño. La depresión a su vez está
sobre-representada en poblaciones con diversos tras-
tornos del sueño. Aunque los trastornos del sueño son
características típicas de la depresión, dichos síntomas
en ocasiones aparecen antes del episodio depresivo.
Las asociaciones bidireccionales entre alteración del
sueño (especialmente el insomnio) y la depresión
aumentan la dificultad para diferenciar las relaciones
causa-efecto entre ellas. Los estudios longitudinales
han identificado consistentemente que el insomnio es
un factor de riesgo para la aparición de un episodio
depresivo o de una recurrencia, y esta asociación se ha
identificado en jóvenes, en adultos de edad media y
en viejos. Los estudios también han mostrado que la
combinación de insomnio y depresión influencian la
evolución de la depresión, aumentando la gravedad
y la duración del episodio como así mismo la frecuen-
cia de recaídas. Afortunadamente estudios recientes
han demostrado que tanto las intervenciones farma-
cológicas como no farmacológicas para el insomnio
pueden reducir favorablemente e incluso prevenir la
depresión. En conjunto estos hallazgos sugieren que
los síntomas relacionados con el sueño que están pre-
sentes antes, durante y/o después de un episodio
depresivo son factores potencialmente modificables
que pueden jugar un importante papel para conse-
guir y mantener la remisión de la depresión. 
Troubles du sommeil au cours de la 
dépression : facteurs de risque de 
dépression ultérieure et implications 
thérapeutiques
La majorité des patients déprimés présentent des
troubles du sommeil. La dépression est également
sur-représentée parmi les sujets souffrant  de
troubles du sommeil variés. Bien que ceux-ci soient
des symptômes typiques de la dépression caractéri-
sée, ils apparaissent parfois avant l’épisode dépres-
sif. L’existence d’un lien  bidirectionnel entre les
troubles du sommeil (en particulier l’insomnie) et la
dépression accroît la difficulté d’en différencier la
relation cause-effet. Des études longitudinales ont
clairement identifié l’insomnie comme facteur de
risque d’une rechute ou une récidive dépressive,
cette association ayant été identifiée chez les
adultes jeunes, d’âge moyen ou plus vieux. Des
études ont aussi permis d’observer que l’insomnie
associée à la dépression influe sur son pronostic,
avec augmentation de la sévérité et de la durée des
épisodes ainsi que du taux de récidives.
Heureusement, des études récentes ont démontré
que des traitements pharmacologiques comme non
pharmacologiques de l’insomnie peuvent réduire
et éventuellement prévenir la dépression. Ces résul-
tats indiquent que les symptômes liés au sommeil
présents avant, pendant et/ou après un épisode
dépressif sont des facteurs potentiellement modi-
fiables, pouvant jouer un rôle important dans l’ob-
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